NCT00503711View on ClinicalTrials.gov

Phase I Chinese PK

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Advanced Solid, Malignant Tumors
Interventions
DRUG

Vandetanib

100 mg every other day, 100mg once daily

DRUG

Vandetanib 300 mg

300mg once daily

Trial Locations (1)

Unknown

Research Site, Guangzhou

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00503711 - Phase I Chinese PK | Biotech Hunter | Biotech Hunter